Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million.

The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capital with strategic expertise, operational capabilities and a global network of founders, investors and academic partners. It also reinforces Angelini Ventures' strategy of backing differentiated healthcare technologies that address significant unmet medical needs and enable more connected and scalable models of care. Through ResMed's planned integration of Noctrix Health's technology into its broader sleep health ecosystem, the acquisition has the potential to expand patient access and enhance the delivery of care.

Founded in 2016, Noctrix Health is a medical technology company focused on developing wearable, clinically validated neuromodulation therapies for chronic neurological and sleep-related conditions. Its lead product, Nidra, is the first FDA-authorized non-invasive therapy for moderate-to-severe Restless Legs Syndrome (RLS), offering a differentiated treatment option for millions of patients affected by the condition globally.

Angelini Ventures invested in Noctrix Health in 2024 as part of the company's $40 million Series C financing round, alongside leading healthcare investors, supporting the company's next phase of clinical and commercial growth.